ÔçÒÒŮѸÀ×

    1. <form id=SSjMaZxIp><nobr id=SSjMaZxIp></nobr></form>
      <address id=SSjMaZxIp><nobr id=SSjMaZxIp><nobr id=SSjMaZxIp></nobr></nobr></address>

      Current Value of Holding

      $1.89M

      Shares

      12.1k

      % of Portfolio

      0.01%

      Average Buy Price

      $154

      Avg closing price
      Price range

      41 Paul Tudor Jones II Avis Budget Group Trades

      Paul Tudor Jones II acquired 92k Avis Budget Group shares worth $14.4M. That's 0.11% of their equity portfolio (229th largest holding). The first Avis Budget Group trade was made in Q2 2013. Since then Paul Tudor Jones II bought shares 38 more times and sold shares on 32 occasions. The stake costed the investor $9.88M, netting the investor a gain of 46% so far.

      Avg closing price
      Price range
      Sold 64.7% shares (-22.2k shares) Q2 2025
      Avg closing price $107.92
      Price range $62.86 - $179.30
      Sold 34.8% shares (-18.3k shares) Q1 2025
      Avg closing price $80.75
      Price range $55.49 - $96.02
      Sold 61.8% shares (-85k shares) Q4 2024
      Avg closing price $91.17
      Price range $77.47 - $109.07
      Increased shares by 14.8% (+17.7k shares) Q3 2024
      Avg closing price $90.33
      Price range $67.43 - $112.13
      Sold 0.4% shares (-468 shares) Q2 2024
      Avg closing price $112.13
      Price range $94.75 - $127.91
      Increased shares by 82.3% (+54.3k shares) Q1 2024
      Avg closing price $137.99
      Price range $100.05 - $175.65
      Increased shares by 6.0% (+3.76k shares) Q4 2023
      Avg closing price $182.28
      Price range $160.15 - $200.44
      Increased shares by 148.7% (+37.2k shares) Q3 2023
      Avg closing price $216.74
      Price range $177.89 - $243.05
      Increased shares by 33.6% (+6.3k shares) Q2 2023
      Avg closing price $183.25
      Price range $157.79 - $228.67
      Sold 71.4% shares (-46.8k shares) Q1 2023
      Avg closing price $200.77
      Price range $164.75 - $247.20
      Increased shares by 3.8% (+2.42k shares) Q4 2022
      Avg closing price $200.58
      Price range $155.70 - $243.34
      Increased shares by 27.9% (+13.8k shares) Q3 2022
      Avg closing price $164.37
      Price range $138.25 - $193.91
      Increased shares by 413.5% (+39.7k shares) Q2 2022
      Avg closing price $219.32
      Price range $147.08 - $319.42
      Sold 49.2% shares (-9.31k shares) Q1 2022
      Avg closing price $201.16
      Price range $149.52 - $298.00
      Sold 24.2% shares (-6.03k shares) Q4 2021
      Avg closing price $221.65
      Price range $120.94 - $357.17
      Sold 49.6% shares (-24.6k shares) Q3 2021
      Avg closing price $88.14
      Price range $68.74 - $120.21
      New holding (+49.5k shares) Q2 2021
      Avg closing price $82.90
      Price range $74.21 - $94.24
      Sold -33.9k shares Q1 2021
      Avg closing price $51.67
      Price range $35.44 - $75.00
      New holding (+33.9k shares) Q4 2020
      Avg closing price $35.15
      Price range $28.34 - $40.38
      Sold -63.6k shares Q3 2020
      Avg closing price $30.12
      Price range $22.48 - $36.18

      News about Avis Budget Group Inc and Paul Tudor Jones II

      CARsgen Presents Research Results on Satri-cel in The Lancet and at the 2025 ASCO Annual Meeting

      CARsgen Presents Research Results on Satri-cel in The Lancet and at the 2025 ASCO Annual Meeting

      SHANGHAI , June 1, 2025 /PRNewswire/ --?CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell th...

      prnewswire.com prnewswire.com, 3 months ago
      CARsgen's Satri-cel Abstract Available on ASCO Website

      CARsgen's Satri-cel Abstract Available on ASCO Website

      SHANGHAI , May 22, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell th...

      prnewswire.com prnewswire.com, 4 months ago
      AbelZeta announces clinical data showing preliminary anti-tumor activity for C-CAR031, an armored autologous GPC3 CAR-T, in patients with advanced hepatocellular carcinoma, at ASCO Annual Meeting 2024

      AbelZeta announces clinical data showing preliminary anti-tumor activity for C-CAR031, an armored autologous GPC3 CAR-T, in patients with advanced hepatocellular carcinoma, at ASCO Annual Meeting 2024

      CAR031 study at 9.03-mo median follow up achieves disease control rate (DCR) of 91.3% and objective response rate (ORR) of 56.5% for patients across all dose...

      prnewswire.com prnewswire.com, over 1 year ago

      Embed chart

      Easily embed the chart on your blog or website ¨C it will always update automatically!

      HoMEÔçÒÒŮѸÀ×